Sarepta Therapeutics Announces That U.S. FDA has Accepted Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta ’s Gene Therapy for Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy

Dear Investor,Please find attached a press release by Sarepta Therapeutics regarding the FDA acceptance of filing and priority review  of our partnered DMD asset:https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-us-fda-has-accepted-filing-andDo not hesitate to contact us for any further questions.With best regards,Roche Investor Relations Dr. Bruno EschliPhone: [phone]e-mail:[e-mail] Dr. Sabine Borngr äberPhone: [phone]e-mail:[e-mail] Dr. Birgit MasjostPhone: [phone]e-mail:[e-mail]. Gerard TobinPhone: [phone]e-mail:[e-mail]  Investor Relations North America Loren KalmPhone: [phone]e-mail:[e-mail]  

Source: Roche Investor Update - November 28, 2022 Category: Pharmaceuticals Source Type: news